Skip to main content

Table 2 Association of CDKN2A methylation and clinico-pathological features in colorectal cancers (n = 422)

From: Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing

Feature

 

CDKN2A N(%)

P-value

  

Negative (335; 79.4%)

Methylated (87; 20.6%)

 

Age

Mean (range)

69.3 (37–95)

68.8 (39–89)

0.7292

Tumor size

Mean (range)

49.3 (5–160)

53.5 (4–170)

0.1265

Tumor location

Left-sided

232 (69.5)

40 (46.5)

<0.0001

 

Right-sided

102 (30.5)

46 (53.5)

 

Gender

Female

181 (54.0)

48 (55.2)

0.849

 

Male

154 (46.0)

39 (44.8)

 

Histological subtype

Non-mucinous

19 (5.7)

11 (12.6)

0.0209

 

Mucinous

316 (94.3)

76 (87.4)

 

Tumor grade

G1-2

317 (96.7)

74 (85.1)

<0.0001

 

G3

11 (3.4)

13 (14.9)

 

pT classification

pT1-2

75 (22.9)

14 (16.1)

0.1711

 

pT3-4

253 (77.1)

73 (83.9)

 

pN classification

pN0

180 (55.9)

37 (43.0)

0.0335

 

pN1-2

142 (44.1)

49 (57.0)

 

Vascular invasion

Absent

238 (72.6)

54 (62.1)

0.0568

 

Present

90 (27.4)

33 (37.9)

 

Invasive margin

Pushing

101 (30.9)

21 (24.4)

0.242

 

Infiltrating

226 (69.1)

65 (75.6)

 

Peritumoral lymphocytic inflammation

Absent

251 (76.5)

66 (75.9)

0.897

 

Present

77 (23.5)

21 (24.1)

 

KRAS (codon 12/13)

Wild-type

227 (69.2)

58 (72.5)

0.565

 

Mutation

101 (30.8)

22 (27.5)

 

BRAF (codon V600E)

Wild-type

287 (94.1)

53 (68.8)

<0.0001

 

Mutation

18 (5.9)

24 (31.2)

 

MSI status

MSS/MSI-L

272 (86.6)

62 (76.5)

0.0252

 

MSI-H

42 (13.4)

19 (23.5)